The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal age-associated disease that is characterized by progressive and irreversible scarring of the lung. The pathogenesis of IPF is not completely understood and current therapies are limited to those that reduce the rate of functional decline in patients with mild-to-moderate disease. In this context, new therapeutic approaches that substantially improve the survival time and quality of life of these patients are urgently needed. Our incomplete understanding of the pathogenic mechanisms of IPF and the lack of appropriate experimental models that reproduce the key characteristics of the human disease are major challenges. As ageing is a major risk factor for IPF, age-related cell perturbations such as telomere attrition, senescence, epigenetic drift, stem cell exhaustion, loss of proteostasis and mitochondrial dysfunction are becoming targets of interest for IPF therapy. In this Review, we discuss current and emerging therapies for IPF, particularly those targeting age-related mechanisms, and discuss future therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–224 of 224
Gazdhar, A., Grad, I., Tamò, L., Gugger, M., Féki, A., & Geiser, T. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt513 · Cited by 68
Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project
Couluris, M., Kinder, B. W., Xu, P., Gross-King, M., Krischer, J. P., & Panos, R. J. (2012) · Lung · doi:10.1007/s00408-012-9410-z · Cited by 67
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
Wilkes, D. S., Chew, T., Flaherty, K. R., Frye, S. B., Gibson, K. F., Kaminski, N., Klemsz, M. J., Lange, W., Noth, I., & Rothhaar, K. (2015) · European Respiratory Journal · doi:10.1183/09031936.00105314 · Cited by 67
Keohane, D. J., Schwartz, J., Gundapaneni, B. K., Stewart, M., & Amass, L. (2017) · Amyloid · doi:10.1080/13506129.2017.1301419 · Cited by 59
Rupatadine Protects against Pulmonary Fibrosis by Attenuating PAF-Mediated Senescence in Rodents
Lv, X., Wang, X., Li, K., Wang, Z., Li, Z., Lv, Q., Fu, X., & Hu, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068631 · Cited by 58
Ziegler, P., Schrezenmeier, H., Akkad, J., Brassat, U., Vankann, L., Panse, J., Wilop, S., Balabanov, S., Schwarz, K., Martens, U. M., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1454-x · Cited by 56
Acidic Fibroblast Growth Factor Induces an Antifibrogenic Phenotype in Human Lung Fibroblasts
Becerril, C., Pardo, A., Montaño, M., Ramos, C., Ramírez, R., & Selman, M. (1999) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.20.5.3288 · Cited by 55
Self-citationPhenylbutyric acid inhibits epithelial-mesenchymal transition during bleomycin-induced lung fibrosis
Zhao, H., Qin, H.-Y., Cao, L., Chen, Y., Tan, Z.-X., Zhang, C., & Xu, D. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.10.013 · Cited by 53
Ferrand, M., Kirsh, O., Griveau, A., Vindrieux, D., Martin, N., Defossez, P., & Bernard, D. (2015) · Aging · doi:10.18632/aging.100845 · Cited by 52
Tsang, A. R., Wyatt, H. D. M., Ting, N. S. Y., & Beattie, T. L. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00810.x · Cited by 51
Expression of SIRT1 and SIRT3 varies according to age in mice
Kwon, Y.-H., Kim, J., Lee, C.-Y., & Kim, H. (2015) · Anatomy & Cell Biology · doi:10.5115/acb.2015.48.1.54 · Cited by 48
Huan, C., Yang, T., Liang, J., Xie, T., Cheng, L., Liu, N., Kurkciyan, A., Mena, J. M., Wang, C., Dai, H., et al. (2015) · Scientific Reports · doi:10.1038/srep14910 · Cited by 45
Valproic acid attenuates renal fibrosis through the induction of autophagy
Kawaoka, K., Doi, S., Nakashima, A., Yamada, K., Ueno, T., Doi, T., & Masaki, T. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1365-6 · Cited by 39
Regenerative medicine in the treatment of idiopathic pulmonary fibrosis: current position
Álvarez, D., Levine, M., & Rojas, M. M. (2015) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s49801 · Cited by 38
Self-citationUbiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4
Lear, T., McKelvey, A. C., Rajbhandari, S., Dunn, S. R., Coon, T. A., Connelly, W., Zhao, J. Y., Kass, D. J., Zhang, Y., Liu, Y., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151229 · Cited by 38
Warsinske, H., Wheaton, A. K., Kim, K. K., Linderman, J. J., Moore, B. B., & Kirschner, D. E. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00183 · Cited by 38
Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts
Sanders, Y. Y., Liu, H., Scruggs, A. M., Duncan, S. R., Huang, S. K., & Thannickal, V. J. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0034oc · Cited by 38
Lee, Y.-L., Obiako, B. O., Gorodnya, O. M., Ruchko, M. V., Kuck, J. L., Pastukh, V. M., Wilson, G. L., Simmons, J. D., & Gillespie, M. N. (2017) · Shock · doi:10.1097/shk.0000000000000838 · Cited by 38
Specific correction of a splice defect in brain by nutritional supplementation
Shetty, R. S., Gallagher, C. S., Chen, Y., Hims, M. M., Mull, J., Leyne, M., Pickel, J. M., Kwok, D., & Slaugenhaupt, S. A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr333 · Cited by 36
Rao, S., Zhang, X., Shi, M., Xiao, Y., Zhang, Y., Wang, Y. Y., Chang-zhi, Z., Shao, S., Liu, X., & Guo, B. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.08.08 · Cited by 31
Anti-Fibrotic Effects of Valproic Acid: Role of HDAC Inhibition and Associated Mechanisms
Khan, S., Ahirwar, K., & Jena, G. (2016) · Epigenomics · doi:10.2217/epi-2016-0034 · Cited by 29
Oh, G., Lee, S., Karna, A., Kim, H., Shen, A., Pandit, A., Lee, S., Yang, S., & So, H. (2016) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2016.79.4.257 · Cited by 29
Lu, H., Cook, T. G., Poirier, C., Merfeld‐Clauss, S., Petrache, I., March, K. L., & Bogatcheva, N. V. (2016) · Cell Transplantation · doi:10.3727/096368915x690189 · Cited by 26
Yoon, Y.-S., Lee, Y.-J., Choi, J.-Y., Cho, M.-S., & Kang, J. L. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0513255 · Cited by 22
Cited by
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
The aging lung: Physiology, disease, and immunity
Schneider, J. L., Rowe, J. H., Garcia-de-Alba, C., Kim, C. F., Sharpe, A. H., & Haigis, M. C. (2021) · Cell · doi:10.1016/j.cell.2021.03.005 · Cited by 500
Cui, H., Xie, N., Banerjee, S., Ge, J., Jiang, D., Dey, T., Matthews, Q. L., Liu, R.-M., & Liu, G. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0360oc · Cited by 367
Metadata
- Authors
- Mora, A. L., Rojas, M., Pardo, A., & Selman, M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2017-10-06
- Volume
- 16
- Issue
- 11
- Pages
- 755-772
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2762514850
- Cited by
- 402
- References
- 224
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.